scholarly journals Renal function and safety result after 1 year treatment of zoledronic acid in Chinese women with postmenopausal osteoporosis

2013 ◽  
Author(s):  
Huiyong Shen ◽  
Yue Sun ◽  
Xun Liu
Keyword(s):  
Renal Function ◽  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis ◽  
Chinese Women

scholarly journals Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis

2017 ◽  
Vol 9 (3) ◽  
pp. 284-289 ◽  
Author(s):  
Yue Ding ◽  
Jian-Cheng Zeng ◽  
Fei Yin ◽  
Chun-lin Zhang ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis ◽  
Acute Phase ◽  
Multicenter Study ◽  
Chinese Women

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

2010 ◽  
Vol 29 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Jawl-Shan Hwang ◽  
Lin-Show Chin ◽  
Jung-Fu Chen ◽  
Tzay-Shing Yang ◽  
Po-Quang Chen ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis ◽  
Chinese Women

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

2014 ◽  
Author(s):  
Svetlana Yureneva ◽  
Oksana Yakushevskaya ◽  
Andrey Donnikov ◽  
Sergey Kuznetzov ◽  
Svetlana Mullambaeva ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

scholarly journals Effects of Zoledronic Acid on Renal Function in Patients with Malignant Tumor

2013 ◽  
Vol 24 ◽  
pp. ix73 ◽  
Author(s):  
H. Urakawa ◽  
A. Mitsuma ◽  
M. Sugishita ◽  
T. Shimokata ◽  
S. Tsukushi ◽  
...  
Keyword(s):  
Renal Function ◽  
Zoledronic Acid ◽  
Malignant Tumor

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

2007 ◽  
Vol 62 (8) ◽  
pp. 526-527 ◽  
Author(s):  
Dennis M. Black ◽  
Pierre D. Delmas ◽  
Richard Eastell ◽  
Ian R. Reid ◽  
Steven Boonen ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

2010 ◽  
Vol 77 (1) ◽  
pp. 53-57 ◽  
Author(s):  
Patrice Fardellone ◽  
Bernard Cortet ◽  
Erick Legrand ◽  
Xavier Bresse ◽  
Ségolène Bisot-Locard ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Effectiveness Model

scholarly journals Efficacy of Oral Alendronate Versus Zoledronic Acid on Postmenopausal Osteoporosis

2019 ◽  
Vol 17 (2) ◽  
Author(s):  
Sharif Najafi ◽  
Zahra Rezasoltani ◽  
Kamran Azma ◽  
Saman Nayeb Abbas ◽  
Mehrdad Aghaei ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

scholarly journals The Lasting Effect of Discontinuing Zoledronic Acid On Periprosthetic Bone Mineral Density Five Years After Total Hip Arthroplasty

2021 ◽  
Author(s):  
Allen Herng Shouh Hsu ◽  
Chun-Hsien Yen ◽  
Yu-Der Lu ◽  
Feng-Chih Kuo ◽  
Cheng-Ta Wu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Renal Function ◽  
Zoledronic Acid ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Control Group ◽  
Mineral Density ◽  
Short Term ◽  
Periprosthetic Bone ◽  
Lasting Effect

Abstract Background: Previous study has shown that a short-term use of zoledronic acid (ZA) after cementless total hip arthroplasty (THA) significantly increases bone mineral density (BMD) over the proximal femur and inhibits bone turnover markers (BTMs) after two years. However, could the discontinuation of ZA have a lasting effect is of interest.Method: This is an extension study of a two-year prospective randomized controlled trial on 54 cementless THA treated with either two doses of ZA or placebo. We compared BTMs [alkaline phosphatase (ALP); osteocalcin (OC); procollagen 1 intact N-terminal propeptide (P1NP)], serum calcium, renal function, radiological findings, and functional outcomes (Harris hip score and UCLA activity score) from baseline to 5 years post-THA in 49 patients, and periprosthetic BMD of the seven Gruen zones in 19 patients.Result: All patients had well-functioning hip prostheses, normal renal function, and normal serum calcium levels at 5-year follow-up. At the fifth year, the BMD levels were not statistically different between the two groups, but the change in BMD from baseline (BMD change ratios) in ZA group were significantly increased in zone 2, 4, and 6 as compared with control group. Parallel to that, in ZA group, levels of ALP were significantly lower at the fifth year; OC were significantly lower at the second and the fifth year; P1NP were significantly lower from 6 weeks to 2 years as compared with those in control group.Conclusion: This study demonstrates the lasting effect of a two-dose ZA given within one year after THA on bone metabolism and periprosthetic BMD at five years. The short-term dosing of ZA followed by a 4-year drug holiday had no adverse events and resulted in significant inhibition of periprosthetic bone loss and BTMs.Trial Registration:This extension study on a randomized, open label, single-center clinical trial was conducted under Institutional Review Board of Chang Gung Memorial Hospital Protocol Records 98-1150A3; 105-1296C1; 105-7004D, and was registered July 19th, 2016 on public registry ClinicalTrials.gov trial registration number NCT02838121.

scholarly journals Association between renal function and bone mineral density in healthy postmenopausal Chinese women

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuang Li ◽  
Junkun Zhan ◽  
Yanjiao Wang ◽  
Yi Wang ◽  
Jieyu He ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Renal Function ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Chinese Women ◽  
Mineral Density ◽  
Cross Sectional ◽  
Total Hip ◽  
The Relationship ◽  
Osteoporosis Risk

Abstract Background The relationship between renal function and bone mineral density (BMD) is controversial. The aim of this study was to determine the relationship of renal function with BMD and osteoporosis risk in healthy postmenopausal Chinese women. Methods A cross-sectional study was conducted in 776 healthy postmenopausal Chinese women. Dual-energy X-ray absorptiometry was used to measure BMDs. Clinical, demographic, and biochemical data were obtained at the time of image acquisition. Estimated glomerular filtration rate (eGFR) was calculated using a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results Women with eGFR levels of at least 90 ml/min/1.73m2 had a lower prevalence of osteoporosis compared with women with decreased eGFR levels (60 ml/min/1.73 m2 ≤ eGFR < 90.0 ml/min/1.73 m2). BMDs at femoral neck and total hip were significantly lower in the lower eGFR class than the higher class (0.717 ± 0.106 vs 0.744 ± 0.125 g/cm2, P < 0.01; 0.796 ± 0.116 vs 0.823 ± 0.129 g/cm2, P < 0.01, respectively). eGFR was positively correlated with BMDs at femoral neck and total hip in unadjusted analysis (P < 0.05). After controlling for age, menopausal duration and body mass index (BMI), decreased eGFR was not associated with osteoporosis risk. Conclusions After adjustments for age, menopausal duration and BMI, the decline in renal function was not independently associated with osteoporosis risk in healthy postmenopausal Chinese women.

Sign in / Sign up

Export Citation Format

Share Document